ArticleCurrent protocols2022
An In Vitro Microneutralization Assay for Influenza Virus Serology.
Article in Current protocols, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 23 citations in OpenAlex.
- Pentameric M2e influenza vaccine candidate generates strong immunity with limited survival benefit.Human vaccines & immunotherapeutics · 2026Article
- Stabilized mosaic hemagglutinin immunogens as novel universal influenza virus vaccines.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Mapping hemagglutinin residues driving antigenic diversity in H5Nx avian influenza viruses.Journal of virology · 2026Article
- Population immunity to clade 2.3.4.4b H5N1 is dominated by anti-neuraminidase antibodies.mBio · 2026Article
- Genetic diversity and circulation of influenza A viruses in Italian pig farms: insights from surveillance and vaccination.Porcine health management · 2026Article
- Evaluation of Immunogenicity of Seasonal Influenza Split HA Vaccines Involved With Changes of Vaccine Strains Using Mouse and Human Sera.Microbiology and immunology · 2026Article
- Influenza vaccine based on AS03-adjuvanted chimeric HA induces long-lived stalk-specific plasma cells in bone marrow and lymph nodes of nonhuman primates.Nature immunology · 2025Article
- IFITM3-deficient mice as a model for testing influenza virus vaccines via the intramuscular route.Vaccine · 2025Article
- Article
- An intranasally administered IgM protects against antigenically distinct subtypes of influenza A viruses.Nature communications · 2025Article
- Article
- Concepts and Methods for Predicting Viral Evolution.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Identification of specific neutralizing antibodies for highly pathogenic avian influenza H5 2.3.4.4b clades to facilitate vaccine design and therapeutics.Emerging microbes & infections · 2024Article
- Concepts and methods for predicting viral evolution.bioRxiv : the preprint server for biology · 2024Article
- Article
- Impact of Pre-Existing Immunity and Age on Antibody Responses to Live Attenuated Influenza Vaccine.Vaccines · 2024Article
- Vaccine design via antigen reorientation.Nature chemical biology · 2024Article
- A broadly applicable protein-polymer adjuvant system for antiviral vaccines.EMBO molecular medicine · 2024Article
- mRNA vaccines encoding influenza virus hemagglutinin (HA) elicits immunity in mice from influenza A virus challenge.PloS one · 2024Article
- A computationally optimized broadly reactive hemagglutinin vaccine elicits neutralizing antibodies against influenza B viruses from both lineages.Scientific reports · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Influenza is an infectious respiratory disease with significant morbidity and mortality rates among people of all ages. Influenza viruses spread and evolve rapidly in the human population. Different immune histories, given by previous exposures to influenza virus infections and/or vaccinations, result in a great diversity of humoral and cellular immune responses. Understanding protective immune responses induced against circulating virus strains and potential pandemic strains is vital for infection prevention and disease mitigation. Vaccine formulations for seasonal influenza must be reformulated annually to stay abreast of occurring virus mutations. Assays to measure the capacity of antibodies to neutralize influenza viruses provide a good estimate of protection against future infections with strains similar or identical to those used in the assay. Here, we describe a detailed protocol of our standard in vitro microneutralization assay to assess the neutralization activity of polyclonal sera or purified monoclonal antibodies. © 2022 The Authors. Current Protocols published by Wiley Periodicals LLC. Basic Protocol: Microneutralization assay to assess virus inhibition by serum or monoclonal antibodies Support Protocol 1: Preparation of cDMEM Support Protocol 2: Preparation and aliquoting of TPCK-treated trypsin Support Protocol 3: Inactivation of serum samples by RDE treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.